长城基金医药投资团队：市场短期或维持震荡，继续关注创新药、AI医疗等

Core Viewpoint - The A-share market is experiencing increased volatility and a significant style switch, prompting a focus on potential investment opportunities in the pharmaceutical sector [1] Group 1: Market Outlook - The market is currently in an earnings vacuum, with expectations of positive developments already realized, leading to a likely short-term oscillating trend for the index, which has touched 4000 points [2] - The focus is on sectors that may see a reversal in expectations and acceleration by 2026, particularly in AI applications and innovative pharmaceuticals [2] Group 2: Pharmaceutical Sector Insights - Despite recent underperformance in the pharmaceutical new technology sector (e.g., AI in healthcare), the market has switched styles multiple times this year, indicating potential opportunities in the sector as long as industry trends continue to evolve and stock prices remain low [3] - The innovative drug sector is expected to show improved performance, with a notable increase in revenue for essential innovative drugs and signs of recovery in some generic drug companies [4] - Key catalysts for the innovative drug sector include industry conferences, overseas clinical advancements, business development (BD) transactions, and negotiations for innovative drugs with national insurance [4] - The domestic innovative drug market still holds significant potential, with recent negotiations aligning with market expectations and positive developments in commercial insurance [4]